Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study | NCT00443105 | Trialant
Unknown statusInterventionalPhase 2Updated Mar 5, 2007
Topical Tacrolimus 0.03% Ointment for Intractable Allergic Conjunctivitis: An Open Label Pilot Study
ClinicalTrials.gov ID
NCT00443105
Lead Sponsor
Assaf-Harofeh Medical CenterOTHER_GOV
Overall Status
Unknown status
Study Type
Interventional
Phase
Phase 2
Last Update Posted
Mar 5, 2007Estimated
Brief Summary
The purpose of this study is to determine the efficacy, tolerance and safety of tacrolimus 0.03% ointment in the treatment of intractable allergic conjunctivitis.
Allergic Conjunctivitis
Tacrolimus 0.03% ointment (Protopic)
Ages Eligible for Study
Child (0-17)Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No data available
Eligibility Criteria
Inclusion Criteria:
Subjects included if they were > 5 years old and suffered from intractable allergic conjunctivitis
Exclusion Criteria:
pregnancy or breastfeeding,history of herpetic eye disease,transplant patients concomitant administration of drugs inhibiting cytochrome CYP3A4, hypersensitivity to macrolides
Primary Purpose
Treatment
Allocation
Non-Randomized
Interventional Model
Single Group Assignment
Masking
None (Open Label)
No central contacts
There are no central contacts for this study.
Assaf Harofeh Medical Center, Department of Ophthalmology